RT Journal Article
SR Electronic
T1 SARS-CoV-2 RNA wastewater settled solids surveillance frequency and impact on predicted COVID-19 incidence using a distributed lag model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.21.22270864
DO 10.1101/2022.02.21.22270864
A1 Schoen, Mary E.
A1 Wolfe, Marlene K.
A1 Li, Linlin
A1 Duong, Dorothea
A1 White, Bradley J.
A1 Hughes, Bridgette
A1 Boehm, Alexandria B.
YR 2022
UL http://medrxiv.org/content/early/2022/02/24/2022.02.21.22270864.abstract
AB SARS-CoV-2 RNA concentrations in wastewater settled solids correlate well with COVID-19 incidence rates (IRs). Here, we develop distributed lag models (DLMs) to estimate IRs using concentrations of SARS-CoV-2 RNA from wastewater solids and investigate the impact of sampling frequency on model performance. SARS-CoV-2 N gene and PMMoV RNA concentrations were measured daily at four wastewater treatment plants in California. Artificially reduced datasets were produced for each plant with sampling frequencies of once every 2, 3, 4, and 7 days. Sewershed-specific models that related daily N/PMMoV to IR were fit for each sampling frequency with data from mid-Nov 2020 through mid-July 2021, which included the period of time during which Delta emerged. Models were used to predict IRs during a subsequent out-of-sample time period. When sampling occurred at least once every 4 days, the in- and out-of-sample root mean square error (RMSE) changed less than 7 cases/100,000 compared to daily sampling across sewersheds. This work illustrates that real-time, daily predictions of IR are possible with small error, despite changes in circulating variants, when sampling frequency is once every 4 days or more. However, reduced sampling frequency may not serve other important wastewater surveillance use cases.Competing Interest StatementDD, BH, and BJW are employees of Verily Life SciencesFunding StatementCDC-FOUNDATIONAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Stanford University waived ethical approval for this work. As stated in the text of our paper: The Institutional Review Board of Stanford University determined that this project does not meet the definition of human subject research as defined in federal regulations 45 CFR 46.102 or 21 CFR 50.3 and indicated that no formal IRB review is required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available as indicated in the paper through the Stanford Digital Repository.